Microdosing Mescaline for Health & Longevity - Quick Reference Sheet

Microdosing Mescaline for Health & Longevity

Created on 09/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

Mescaline is a psychedelic from peyote and San Pedro cacti; microdosing means repeatedly administering amounts too small to change perception, aiming to support mood and focus. No controlled study has tested such doses in people. Reported gains come mainly from users who knew they received it, and studies of related psychedelics point to expectation. Higher doses affect blood pressure, heart rate, and digestion. The case for benefit is speculative. (Full Review)

Protocol

Practitioner dose ranges
10–40 mg mescaline salt
About 0.9 g dried peyote or 3.3–10 g dried San Pedro cactus per microdose (Third Wave, a course seller); no validated clinical protocol exists
Fadiman schedule
One dose on day 1, none on days 2–3
Repeated for several weeks, no more than a few months at a time (Third Wave, a course seller)
Time of day
Morning dosing is typical
100 mg lasted a mean of 6.4 hours (Klaiber et al., 2024)
Time to effect
Longer-term benefit
No mescaline data exist
A 4-week blinded microdosing trial saw improvement in both microdose and placebo groups
Acute onset
About 30 minutes
Measured after oral administration in a controlled trial
Peak effect
About 2 hours
Half-life about 3.5 hours after oral administration

Benefits

Contraindications
  • Personal or first-degree family history of psychotic or bipolar disorder
  • Uncontrolled hypertension (sustained at 140/90 mmHg or higher despite treatment)
  • Recent myocardial infarction (heart muscle damage from blocked blood flow) or stroke (within 90 days), or heart failure of New York Heart Association Class III–IV
  • Known moderate or severe valvular heart disease (damaged heart valves)
  • Pregnancy or breastfeeding
  • Age under 25
  • Current lithium or monoamine oxidase inhibitor therapy
  • Harmala-containing herbs (Syrian rue, ayahuasca vine; theoretical)
Key Interactions
  • Serotonin 2A-blocking drugs (ketanserin, risperidone, olanzapine, mirtazapine)
  • Selective serotonin reuptake inhibitors (sertraline, fluoxetine, escitalopram)
  • Blood pressure and heart drugs (amlodipine, lisinopril, metoprolol)
  • Prescription stimulants (amphetamine, methylphenidate)
  • Decongestants (pseudoephedrine, phenylephrine)
  • Dextromethorphan (cough suppressant; theoretical)
  • Caffeine in high doses (energy drinks, pre-workout products)
  • Serotonin-boosting supplements (5-hydroxytryptophan, L-Tryptophan, St. John's wort, S-Adenosylmethionine; theoretical)
  • Stimulant supplements (yohimbine, synephrine, ephedra alkaloids)
  • Alcohol and cannabis
  • Heat exposure and strenuous exercise (sauna, hot yoga, intense training)
  • Other psychedelics (LSD, psilocybin)

Risk & Side Effects

  • High: Blood pressure, heart rate, temperature, and pupil size elevation; nausea, vomiting, headache, and fatigue
  • Medium: Tolerance with repeated dosing; anxiety, agitation, and unintended perceptual effects
  • Low: Impaired cognitive control; psychosis or mania in predisposed individuals; flashbacks and persisting perceptual changes; dependence and misuse; long-term cognitive or psychological harm; fetal harm with use in pregnancy
  • Speculative: Heart valve damage from chronic serotonin 2B receptor activation

Monitoring

Marker Target Why
Resting blood pressure Below 120/80 mmHg Mescaline raises blood pressure at 200 mg and above
Resting heart rate 50–70 beats per minute Heart rate rises with dose
Electrocardiogram Normal rhythm and conduction Screens for arrhythmia (irregular heartbeat) before stimulant-like exposure
Echocardiogram (heart ultrasound) No more than trivial valve leakage Baseline for the unresolved serotonin 2B valve concern
Estimated glomerular filtration rate 90 mL/min/1.73 m² or higher About half of a dose is excreted unchanged by the kidneys
Depression symptom score 0–4 (minimal) Tracks the claimed mood benefit against baseline
Anxiety symptom score 0–4 (minimal) Anxiety is a reported adverse effect
Cognitive control task (for example, a Stroop test) No established target; track change from own baseline Pooled microdosing studies show a small loss of cognitive control
Inflammation marker (high-sensitivity C-reactive protein) Below 1.0 mg/L Tests the speculative anti-inflammatory claim

Cadence: Baseline before a first dose; blood pressure and heart rate at the first dose, weekly for the first month, then monthly during courses; mood, anxiety, and cognitive scores at baseline, week 4, and course end, then every 3–6 months; echocardiogram and kidney function every 12 months with continued use

Qualitative Assessment

  • Sleep quality and morning refreshment
  • Daytime energy and next-day fatigue
  • Mood stability and anxiety
  • Focus and cognitive clarity
  • Signs of tolerance, such as needing higher doses for the same effect
  • Blinded self-ratings compared across dosing and non-dosing days